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ABSTRACT  
Objective: This study aims to develop and validate a stability indicating HPLC method for simultaneous estimation of sacubitril and valsartan in 
pharmaceutical dosage form.  
Methods: Sacubitril and valsartan separation were achieved by LC-20 AT C18 (250 mm x 4.6 mm) column and buffer (potassium phosphate, pH 3.0): 
methanol (50:50) as mobile phase, at a flow rate of 1 ml/min (millilitre per minute). Detection was carried out at 224 nm (nanometer). The different 
HPLC experimental parameters were optimized and the method was validated according to the standard guideline. Forced degradation experiments 
were carried out by exposing sacubitril and valsartan standard and sample for thermal, photolytic, oxidative and acid-base hydrolytic stress conditions. 
Results: Retention time of sacubitril and valsartan were found to be 4.170 min (minute) and 6.530 min (minute) respectively. The method has been 
validated for linearity, accuracy, precision, LOD, and LOQ. Linearity observed for sacubitril is 12.25-36.75 μg/ml (microgram per milliliter) and for 
valsartan is 12.75-38.25 μg/ml (microgram per milliliter). The results showed that sacubitril and valsartan and the other degradation products 
were fully resolved and thus the proposed method is stability-indicating. 
Conclusion: The proposed HPLC method was found to be simple, specific, precise, accurate, rapid and economical for simultaneous estimation of 
valsartan and sacubitril in bulk and tablet dosage form. Thus the validated economical method was applied for forced degradation study of 
sacubitril and valsartan tablet. 
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Sacubitril is chemically 4-[[(2S, 4R)-5-ethoxy-4-methyl-5-oxo-1-(4-
phenyl-phenyl) pentan-2-yl] amino]-4-oxobutanoic acid [1]. Sacubitril 
is an antihypertensive drug used in combination with valsartan for the 
treatment of heart failure. [2-3]. Valsartan is a nonpeptide, orally 
active and specific angiotensin II receptor blocker acting on the AT1 
receptor subtype. Valsartan is chemically N-(1-oxopentyl)-N-[[2'-
(1Htetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-Lvaline [4-7]. Methods 
such as HPLC [8-10], LC-MS [11-12], protein precipitation [13] and 
simultaneous UV-spectrophotometric methods [14-15] are reported 
for estimation of valsartan alone or in combination with other agents. 
A literature search reveals that only two analytical methods were 
reported for simultaneous estimation of sacubitril and valsartan from 
rat plasma using LC-MS/MS [16] and from a synthetic mixture using 
HPLC [17]. There is no stability indicating analytical methods were 
reported for simultaneous estimation of sacubitril and valsartan. 
Hence a simple, rapid, sensitive and accurate stability indicating HPLC 
method was developed for the simultaneous estimation of sacubitril 
and valsartan from API and pharmaceutical dosage form. 
 
  
Fig. 1: Sacubitril structure from pub chem Fig. 2: Valsartan structure from pub chem 
 
MATERIALS AND METHODS [17] 
Materials and reagents 
Acetonitrile, potassium di-hydrogen phosphate, orthophosphoric 
acid and methanol of HPLC and AR grade were procured from Merck 
and Rankem lab ltd. Sacubitril and valsartan standards were 
received as gift samples from Yash Pharma and RPG Life Science, 
Ahmedabad, India, respectively. 
Equipment 
Chromatographic separation was performed on HPLC system 
consist of model Shimadzu LC-20 AT having a SPD-20AT detector 
and rheodyne injector with 20μl loop volume. Spinchrom 
software was applied for data collecting and processing. UV 
spectrophotometer which consists of model Systronic 119 is also 
used to measure the wavelength of the solution of Sacubitril and 
Valsartan. 
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Preparation of standard stock solution  
Accurately weighed quantity of 24.5 mg (milligram) sacubitril and 
25.5 mg (milligram) valsartan API were transferred into 100 ml 
(milliliter) volumetric flask and dissolved in HPLC grade methanol 
using ultra sonication and diluted up to mark to give a stock solution 
having concentration of 245 μg/ml sacubitril and 255 μg/ml 
valsartan. 
Preparation of working standard solution  
From above standard stock solution of sacubitril and valsartan, 1 ml 
of solution was taken into 10 ml volumetric flask and was made to 
the mark with the mobile phase to get 24.5 μg/ml of sacubitril and 
25.5 μg/ml of valsartan. 
Preparation of sample stock solution 
The average weight of 10 tablets was determined and was ground in 
a mortar. Sample stock solution was prepared by dissolving tablet 
powder equivalent to 24.5 mg of sacubitril or 25.5 mg of valsartan 
was transferred to 100 ml volumetric flask. Then 60 ml methanol 
was added and sonicated for 5 min to ensure complete solubilization 
of drug. After sonication, volume was made up to the mark with 
methanol. Filter the stock solution with whatman filter paper and 
the final filtrate is collected as sample stock solution. 
Chromatographic conditions 
A BDS hypersil C18 (250*4.6 mm, 5 µm) column was used as the 
stationary phase. A mixture of buffer (pH 3.0) and methanol in the 
ratio of (50:50 %v/v) was used as a mobile phase and pH 3.0 
adjusted with ortho phosphoric acid. It was filtered through 0.45μ 
(micron) membrane filter and degassed. The mobile phase was 
pumped at 1.0 ml/min. The eluents were monitored at 224 nm. The 
injection volumes of sample and standard were 20μl (microliter). 
Total run time is 10 min. 
 
 
Fig. 3: Chromatogram of sacubitril and valsartan 
 
The developed Method was validated for linearity, precision, 
accuracy, robustness and is applied for forced degradation studies as 
per the ICH guidelines [18-23] 
RESULTS AND DISCUSSION 
Method validation 
The described method has been validated which include parameters 
like system suitability, linearity, accuracy, precision, robustness, 
LOD (limit of detection) and LOQ (limit of quantification). 
System suitability 
System suitability and chromatographic parameters were validated 
such as resolution, theoretical plates, and the tailing factor was 
calculated. The results are given in table 1. 
 
Table 1: System suitability parameters for sacubitril and valsartan 
System suitability parameter Sacubitril Valsartan 
Retention time (min) 4.170 6.530 
Theoretical plate number (N) 4915 6320 




The linearity of this method was evaluated by linear regression 
analysis and calculated by the least square method and studied by 
preparing standard solutions of sacubitril and valsartan at different 
concentration levels. The calibration curve showed (Fig. 4 and 5) 
good linearity in the range of 12.25-36.75 μg/ml, for sacubitril with 
a correlation coefficient (r2) of 0.999 and 12.75-38.25 µg/ml for 
valsartan with a correlation coefficient (r2) of 0.999. Results are 
given in table 2. 
 
Table 2: Linearity data for sacubitril and valsartan 
Drug Conc* (µg/ml) Area  
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Fig. 4: Calibration curve of sacubitril 
 
 
Fig. 5: Calibration curve of valsartan 
 
Accuracy 
Recovery studies were carried out by addition of the standard drug 
to the sample at 3 different concentration levels (80%, 100% and 
120%) taking into consideration percentage purity of added bulk 
drug samples. At each concentration, the sample was injected thrice 
to check repeatability and from the % RSD values it was analyzed 
that the method was accurate as % recovery values found to be in 
the range of 99.72-100.02% for the Sacubitril and 99.87-100.17 % 
for valsartan at three different concentrations 80%, 100%, 120%. 
 The results are given in table 3 and 4. 
 













80% 12.25 9.8 9.674 98.71 99.61±0.79 
12.25 9.8 9.796 99.96 
12.25 9.8 9.816 100.16 
100% 12.25 12.25 12.129 99.01 99.57±0.53 
12.25 12.25 12.259 100.07 
12.25 12.25 12.203 99.61 
120% 12.25 14.7 14.694 99.96 99.59±0.41 
12.25 14.7 14.574 99.14 
12.25 14.7 14.650 99.66 
SD*-standard deviation, Conc*-concentration, Number of experiments (n)-3 
 
Table 4: Accuracy data for valsartan 






% recovery % mean recovery±SD* 
80% 12.75 10.2 10.067 98.70 99.92±1.13 
12.75 10.2 10.294 100.92 
12.75 10.2 10.215 100.15 
100% 12.75 12.75 12.622 99.00 99.63±0.65 
12.75 12.75 12.88 100.30 
12.75 12.75 12.699 99.60 
120% 12.75 15.3 15.317 100.11 99.63±0.49 
12.75 15.3 15.168 99.13 
12.75 15.3 15.247 99.65 
SD*-standard deviation, Conc*-concentration, Number of experiments (n)-3 
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A standard solution containing sacubitril (24.5 µg/ml) and valsartan 
(25.5 µg/ml) was injected six times and areas of peaks were measured 
and % RSD was calculated. The results are given in table 5. 
Intraday precision 
A standard solution containing (12.25,24.5,36.75 µg/ml) of 
sacubitril and (12.75,25.5,38.25 µg/ml) of valsartan were analyzed 
three times on the same day and % R. SD was calculated. The results 
are given in table 6. 
Interday precision 
A standard solution containing (12.25, 24.5, 36.75µg/ml) of 
sacubitril (12.75, 25.5, 38.25 µg/ml) of valsartan were analyzed 
three times on a different day and % RSD was calculated. The results 
are given in table 7. 
 
Table 5: Repeatability data for sacubitril and valsartan 
Drug Conc* (µg/ml) Area Mean±SD*(n=6) % RSD* 












SD*-standard deviation, RSD*-relative standard deviation, Conc*-concentration, Number of experiments (n)-6 
 
Table 6: Intraday data for sacubitril and valsartan 
Drug Conc* (µg/ml) Area mean±SD* (n=3) % RSD* 
Sacubitril 12.25 2223.62±15.41 0.63 
24.5 4475.65±51.86 1.16 
36.75 6728.43±32.64 0.49 
Valsartan 12.75 1858.60±20.77 1.12 
25.5 3745.33±51.48 1.37 
38.25 5617.50±69.47 1.24 
SD*-standard deviation, RSD*-relative standard deviation, Conc*-concentration, Number of experiments (n)-3 
 
Table 7: Interday data of sacubitril and valsartan 
Drug Conc* (µg/ml) Area mean±SD* (n=3) % RSD* 
Sacubitril 12.25 2218.93±17.50 0.79 
24.5 4480.94±30.84 0.69 
36.75 6727.83±20.15 0.30 
Valsartan 12.75 1850.82±28.78 1.55 
25.5 3732.18±63.54 1.70 
38.25 5619.57±45.30 0.81 
SD*-standard deviation, RSD*-relative standard deviation, Conc*-concentration, Number of experiments (n)-3 
 
Robustness 
Small deliberate changes in chromatographic conditions such as a 
change in mobile phase ratio (+2 %), change in pH (±2 units) and 
flow rate (±2 units) were studied to determine the robustness of the 
method. The results were in the factor of (% RSD<2%) the 
developed RP-HPLC method for the analysis of sacubitril and 
valsartan. The results are given in table 8 and 9. 
 
Table 8: Robustness data for sacubitril 
Drug Area at flow rate 
(-0.2 ml/min) 
Area at flow 
rate (+0.2 ml/min) 
Area at 
pH (-0.2) 
Area at pH 
(+0.2) 
Area at mobile 
phase(-2) 
Area at mobile phase (+2) 
Sacubitril 4628.12 4366.85 4577.39 4252.50 4580.41 4334.83 
4688.80 4417.00 4643.53 4326.41 4629.58 4408.15 
4706.76 4435.21 4661.51 4353.43 4656.83 4439.65 
% RSD* 0.88 0.80 0.96 1.21 0.84 1.22 
 RSD*-relative standard deviation, Number of experiments (n)-3 
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Table 9: Robustness data for valsartan 
Drug Area at flow rate 
(-0.2 ml/min) 




Area at pH (+0.2) Area at mobile 
phase (-2) 
Area at mobile phase 
(+2) 
Valsartan 3917.08 3681.51 3879.05 3605.61 3875.17 3674.13 
3827.40 3601.23 3894.17 3526.61 3777.54 3696.78 
3947.18 3719.47 3909.24 3650.86 3909.63 3723.20 
% RSD* 1.60 1.65 0.39 1.75 1.78 0.66 
 RSD*-relative standard deviation, Number of experiments (n)-3 
 
Limit of detection (LOD) and limit of quantification (LOQ) 
The LOD and LOQ were found to be 0.85µg/ml and 2.580µg/ml for 
sacubitril and 0.89µg/ml and 2.687µg/ml for valsartan estimated by 
using the standard formulas. The low values of LOD and LOQ 
illustrate that the developed method was sensitive, accurate and 
precise as it can detected and quantify with very low concentration. 
The result is given in table 10. 
 
Table 10: LOD and LOQ data for sacubitril and valsartan 
Drug  LOD* LOQ* 
Sacubitril 0.85(µg/ml) 2.580(µg/ml) 
Valsartan 0.89(µg/ml) 2.687(µg/ml) 
 LOD*-limit of detection, LOQ*-limit of quantification 
 
Method development 
ICH prescribed stress conditions such as acidic, basic, oxidative, 
thermal and photolytic stresses were carried out. 
Acid degradation  
Acid decomposition studies were performed by refluxing 1 ml of 
sample stock solution was transferred into 10 ml of volumetric flask. 
2 ml of 0.1 N HCl solutions were added and mixed well and put for 4 
h at 70 °C 250 ml round bottom flask. After a time period, the 
content was cooled to room temperature. Then the volume was 
adjusted with diluent to get 24.5μg/ml for sacubitril and 25.5μg/ml 
for valsartan. After making final solutions, it is injected into HPLC 
and the peak area and peak shapes were observed. Chromatogram 
of acid degradation on sample solution is shown below in fig. 6. 
Base degradation  
Basic decomposition studies were performed by refluxing 1 ml of 
sample stock solution was transferred into 10 ml of volumetric flask. 
2 ml of 0.1 N NaOH solutions were added and mixed well and put for 
4 h at 70 °C 250 ml round bottom flask. After a time period the 
content was cooled to room temperature. Then the volume was 
adjusted with diluent to get 24.5μg/ml for sacubitril and 25.5μg/ml 
for valsartan. After making final solutions, it is injected into HPLC 
and the peak area and peak shapes were observed. Chromatogram 
of base degradation on sample solution is shown below in fig. 7. 
 
 
Fig. 6: Sacubitril and valsartan acid degradation sample at 4 h 
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Fig. 7: Sacubitril and valsartan base degradation sample at 4 h 
Oxidative degradation  
Oxidative decomposition studies were performed by refluxing 1 ml 
of sample stock solution was transferred into 10 ml of volumetric 
flask. 2 ml of 3% H2O2 solutions was added and mixed well and put 
for 4 h at 70 °C 250 ml round bottom flask. After a time period, the 
content was cooled to room temperature. Then the volume was 
adjusted with diluent to get 24.5μg/ml for sacubitril and 
25.5μg/ml for valsartan. After making final solutions, it is injected 
into HPLC and the peak area and peak shapes were observed. 
Chromatogram of oxidative degradation on sample solution is 
shown below in fig. 8. 
 
 
Fig. 8: Sacubitril and valsartan oxidation degradation sample at 4 h 
 
Thermal degradation  
Thermal degradation studies were performed by taking 1 ml of 
sample stock solution was transferred into 10 ml of volumetric flask. 
The volumetric flask was stored in an oven at 110 °C for 4 h. Then 
the volume was adjusted with diluent to get 24.5μg/ml for sacubitril 
and 25.5μg/ml for valsartan. After making final solutions, it is 
injected into HPLC and the peak area and peak shapes were 
observed. Chromatogram of thermal degradation on sample solution 
is shown below in fig. 9. 
 
 
Fig. 9: Sacubitril and valsartan thermal degradation sample at 4 h 
 
Photolytic degradation  
Photo degradation studies were performed by taking 1 ml of sample 
stock solution was transferred into 10 ml of volumetric flask. The 
volumetric flask was kept in UV chamber for 72 h. Then the volume 
was adjusted with diluent to get 24.5 μg/ml for sacubitril and 
25.5μg/ml for valsartan. After making final solutions it is injected 
into HPLC and the peak area and peak shapes were observed. 
Chromatogram of photo degradation on sample solution is shown 
below in fig. 10. 
 
 
Fig. 10: Sacubitril and valsartan photo degradation sample at 72 h 
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Table 11: Stability data for sacubitril and valsartan 
Sacubitril standard area for stability–4827.067 
Parameter Standard Sample 
Area % degradation Area % degradation 
Acid 3613.169 25.148 3885.979 19.496 
Base 3937.527 18.428 4059.528 15.901 
Oxidation 3638.838 24.616 3645.262 24.483 
Thermal 3930.438 18.575 4050.228 16.093 
Photo 4184.313 13.316 4330.211 10.293 
Valsartan standard area for stability–4160.168 
Parameter Standard Sample 
Area % degradation Area % degradation 
Acid 3607.113 13.294 3743.630 10.013 
Base 3355.132 19.351 3474.849 16.473 
Oxidation 3613.807 13.133 3459.645 16.839 
Thermal 3069.332 26.221 3026.332 27.255 
Photo 3612.071 13.175 3654.960 12.144 
 
Sacubitril and valsartan undergoes significant degradation in acid, 
base, peroxide, thermal and UV. Comparatively, more degradation was 
found with acid and peroxide for sacubitril and with thermal for 
valsartan. Hence, a method of the analysis of sacubitril and valsartan in 
tablet dosage form shows that the degradation product doesn’t 
interfere with the analytical determination. Hence the proposed 
analytical method is also useful for the determination of sacubitril and 
valsartan stability in a sample of the pharmaceutical dosage form. 
CONCLUSION 
Stability indicating RP-HPLC methods have been developed and 
validated for the determination of sacubitril and valsartan in tablet 
dosage form. The methods are found to be specific as there was no 
interference of any co-eluting impurities after stress degradation 
study. The degraded products are well resolved, indicating the method 
can also be useful for determination of degraded products. The 
proposed method is found to be simple, accurate, precise and robust. 
Hence, it can be used successfully for the routine analysis of sacubitril 
and valsartan in pharmaceutical dosage forms and for analysis of 
stability samples obtained during accelerated stability study. 
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